Meril Announces Prestigious LANCET Publication for Landmark RCT of the MYVAL THV Series, Researched and Developed by INDIA
Meril Announces Prestigious LANCET Publication for Landmark RCT of the MYVAL THV Series, Researched and Developed by INDIA
Meril Life Sciences is proud to announce that its LANDMARK randomized controlled trial (RCT) for the MYVAL THV series has been published in the prestigious medical journal The Lancet.
This recognition underscores the significance and impact of the MYVAL THV series, a pioneering medical device researched and developed entirely in India.
Chennai, June 19th, 2024: Meril Life Sciences, an India-based global medical device company, recently conducted a trial study titled ‘Comparison of Early Outcomes of Newer-Generation Myval Transcatheter Heart Valve Series with Contemporary Valves (Sapien and Evolut) THV Series in Real-World Individuals with Severe Symptomatic Native Aortic Stenosis: A Randomised Non-Inferiority Trial’. The LANDMARK randomized controlled trial for the MYVAL THV series has been published in The Lancet, a prestigious medical journal.
Sharing details about the same, Prof. Andreas Baumbach, Global Principal Investigator said, “The Landmark trial showed that the Myval THV series performed as safely and effectively as contemporary THV series. It is a valve made for everyday clinical practice and an all-comers population. The special feature of intermediate diameters allows for more accurate sizing, which has the potential to translate into improved long-term outcomes. Our patients will be followed up for 10 years and it will be interesting to see the long-term results in the three treatment arms.”
This pivotal research compares early outcomes of the new-generation Myval THV series with contemporary (Sapien and Evolut) THV series in real-world patients suffering from severe symptomatic native aortic stenosis (AS). The findings highlight that the Myval THV series is non-inferior to global giants.
On the milestone achievement Interventional cardiologist Dr G.Sengottuvelu, said, “We are elated and proud at being the first medical device company in India to research and develop MYVAL THV series. Being featured in Lancet underscores the significance and impact of the MYVAL THV series. Also, this has proved India’s capability to set new standards in cardiovascular care, revolutionising heart valve treatment worldwide. This trial also reiterates the success of the ‘Make in India’ initiative.”
Comments
Post a Comment